ICON today announced that its Firecrest training meets TransCelerate BioPharma Inc.’s minimum criteria for International Conference on Harmonisation Good Clinical Practice (ICH/GCP) training.
ICON today announced that it has been named Best Clinical Research Organisation in the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place in Washington last week.
ICON today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5 million. Aptiv Solutions is owned by The Halifax Group, SV Life Sciences, Comvest Partners and Management.
ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 56% year on year. Full Year 2013 Revenue was $1.34 billion, up 20% year on year, EPS was $1.77 up 77% year on year. Guidance issued for 2014.
ICON today announced the appointment of Ms. Mary Pendergast, J.D., LL.M., as a non-executive director
ICON today announced the appointment of Dr. Dariush Elahi as Director of Metabolic Research
ICON today announced that its Chief Executive, Ciaran Murray, has been elected 2013 Chairman of the Association of Clinical Research Organisations (ACRO).
ICON today announced that Dr. Steve Cutler has been appointed to the newly created position of Chief Operating Officer (COO), ICON plc.
ICON today announced that it has appointed Mr. Manuel Ploch as General Manager, Japan.
ICON today announced ICONIK Labs, the latest service to leverage its ICONIK technology platform